A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Non-small Cell Lung Cancer, NSCLC

In brief

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with high levels of programmed cell death ligand-1 (PD-L1), locally advanced/recurrent or untreated metastatic non-small cell lung cancer (NSCLC).

Key facts

Study ID
NCT04746924
Run by
BeiGene
People needed
669
Starts
2021-05-24
Expected to finish
2026-03-18
Last updated by the study team
2026-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.